In an interview, BrightInsight Co-founder and CEO Kal Patel, MD, offered a preview of the report, The Role of Digital Health in Immuno-oncology Therapy Development and Adoption.
The company plans to start clinical development next year. Its focus is on bispecific antibodies - a form of cancer immunotherapy - that use gamma-delta "surveillance" T cells.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The designation, for the PD-1 inhibitor toripalimab in nasopharyngeal carcinoma, makes the Shanghai-based company the latest of several Chinese biotech firms to make headway in the U.S. market.
The drugmaker's equity investment is just the latest in a string of large biopharma companies making moves into the emerging space of cancer immunotherapy drugs targeting CD47. AbbVie announced a $2 billion deal with I-Mab last week, while Gilead spent $4.9 billion to buy Forty Seven in March.
Under the 10-year deal, Gilead will have the right to option product candidates from Arcus' pipeline, with the companies sharing responsibility for development and commercialization.
Experts weighed in on how the move could change the way drugmakers raise money for development programs. But as digital securities as a financial instrument gain traction, they could carry potential risks too.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
The drugmaker called its offering, scheduled for next month and meant to finance development of the drug AGEN2034, a first in healthcare and said it expects others to use the same means to raise capital.
Immuno-oncology is on a roll, yet many questions remain unanswered. What incites an immune response and where does the future of the field lie?
After Bristol-Myers Squibb reported that its Opdivo lung cancer trial unexpectedly failed, perhaps a wholesale reset of cancer immunotherapy's drug development, approval and payment is necessary.
BMS' purchase of Cormorant shows that no deal is too small when it comes to immuno-oncology.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
With the Cancer Moonshot initiative in the spotlight today, here are some insights to consider in the race to develop immuno-oncology drugs.
Forty Seven has licensed more than 100 patents from Stanford University that are related to the company's lead therapeutic, monoclonal antibody Hu5F9-G4, as well as a number of novel immune checkpoint inhibitors and cancer-specific antibodies.
BeneVir's cancer vaccines are engineered to incite an immune response, as well as hide from the immune system - so as to have a prolonged anti-cancer effect.
Another load of cash - and little further insight - is on the books for Patrick Soon-Shiong cancer immunotherapy startup NantCell.
Also, Teva talks drug prices; security wonks talk medical device hacks, and ugly talk at the Anthem-Aetna hearings.